Could Psoriasis Trigger Skin, Lung Cancer, and Lymphoma Risk?

Article

Psoriasis patients may be at higher risk for developing cancers like nonmelanoma skin cancer, lymphoma, and lung cancer.

Psoriasis patients may be at higher risk for developing cancers like nonmelanoma skin cancer, lymphoma, and lung cancer.

According to a study recently published in JAMA Dermatology, several factors associated with psoriasis‑‑particularly its chronic inflammatory nature, the use of immunosuppressive and ultraviolet therapies, the increased prevalence of smoking and obesity‑‑are attributed to the correlation between psoriasis and cancer.

As such, researchers compared the overall risk of cancer in psoriasis patients with the risk in patients not suffering from psoriasis to identify specific “cancers of interest”.

The team analyzed data from The Health Improvement Network of 198,366 patients with psoriasis and 937,716 patients without psoriasis.

Results indicated there was a small increased risk for any incident of cancer (excluding nonmelanoma skin cancer) in the psoriasis- afflicted patient group. The study authors concluded, “The association between psoriasis and cancer, albeit small, was present in our cohort of patients with psoriasis, this association was primarily driven by non-melanoma skin cancer, lymphoma, and lung cancer.”

Recent Videos
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
© 2024 MJH Life Sciences

All rights reserved.